Five Point Infrastructure Announces the Formation of PowerBridge With a $1 Billion Equity Commitment, to Develop and Build Gigawatt-Scale Powered Data Center Campuses in North America
HOUSTON--(BUSINESS WIRE)--May 15, 2025--
Five Point Infrastructure LLC (formerly known as Five Point Energy, 'Five Point') today announced the formation and funding of PowerBridge LLC ('PowerBridge' or the 'Company'), with an equity commitment of up to $1 billion. PowerBridge is focused on developing, building, and managing gigawatt-scale data center campuses, associated power infrastructure and fiber network connectivity throughout North America.
The formation of PowerBridge builds on Five Point's powered land strategy, developing significant digital infrastructure projects that require abundant and reliable power and related infrastructure. Through affiliate company LandBridge (NYSE: LB), a leading land management business, PowerBridge will immediately gain access to more than 275,000 surface acres for infrastructure development, as well as direct access to low cost natural gas due to LandBridge's strategic positioning adjacent to the Waha Gas market hub. The platform will also uniquely benefit from its relationship with Five Point backed WaterBridge, a pioneer of water management and the largest pureplay, privately-held midstream water management company in the Delaware Basin, in addressing the cooling water needs of data centers and new power generation.
PowerBridge is led by CEO Alex Hernandez. Prior to founding PowerBridge, Mr. Hernandez was Founder and CEO of Cumulus Data and CEO of Talen Energy Corp (NASDAQ: TLN), one of the largest competitive power companies in North America with ~15 GW of power generation assets. Cumulus Data was sold to Amazon Web Services (AWS) in May 2024. Mr. Hernandez currently serves on the Board of Directors of ERCOT, which manages the flow of electric power to 27 million Texas customers and 90 percent of the state's electric load.
Mr. Hernandez said, 'We are excited to partner with Five Point to capitalize on this generational moment in the growth and convergence of energy and digital infrastructure. With Five Point's institutional support, our collective energy infrastructure, power operations, data center development, and fiber experience, and the significant additional value that other Five Point portfolio companies can bring for customers, we look forward to providing hyperscale customers with turnkey data center campus solutions at scale.'
The PowerBridge team, including Mr. Hernandez and other former Cumulus executives, is the only team to successfully develop and deliver a gigawatt-scale data center campus directly connected to wholesale power generation assets, without a grid connection. The 1 GW Cumulus data center campus was directly connected to Talen Energy's 2.6 GW Susquehanna Nuclear Power Plant in Berwick, PA. Validating the success of this project, AWS is in the process of deploying approximately $12 billion of capital into this digital giga-campus by constructing 17 data center buildings (~960 MW in aggregate). The team that developed this campus has been re-assembled to execute similar digital giga-campus deployments within PowerBridge.
David Capobianco, CEO and Managing Partner of Five Point, said, 'The formation of PowerBridge adds another important component to our powered land strategy. Together with Landbridge, WaterBridge, our deep institutional relationships and track record of building critical infrastructure companies, PowerBridge is well positioned to create best-in-class data, power, and fiber solutions for data center customers.' Mr. Capobianco continued, 'Alex and his team transformed the power and data center industries with the Cumulus project, and we firmly believe this experience, combined with our resources, will redefine the digital infrastructure landscape once again by providing a differentiated, integrated and competitive solution at multi-gigawatt scale.'
About PowerBridge LLC
PowerBridge develops, builds and manages gigawatt-scale data center campuses and associated power infrastructure and network connectivity throughout North America. For more information, please visit www.power-bridge.com
About Five Point Infrastructure
Five Point Infrastructure LLC (formerly known as Five Point Energy LLC) is a private equity and infrastructure investor focused on investments within the North American powered land, surface management, water management, and sustainable infrastructure sectors. The firm was founded by industry veterans with demonstrated records of success investing in, building, and running infrastructure companies. Based in Houston, Texas, Five Point has approximately $8 billion of assets under management across multiple investment funds. For further information, please visit www.fpinfra.com.
About LandBridge
LandBridge (NYSE: LB) owns approximately 277,000 surface acres across Texas and New Mexico, located primarily in the heart of the Delaware sub-region in the Permian Basin, the most active region for oil and gas exploration and development in the United States. LandBridge actively manages its land and resources to support and encourage energy and infrastructure development and other land uses, including digital infrastructure. LandBridge was formed by Five Point. For more information, please visit: www.landbridgeco.com.
About NDB Midstream and WaterBridge Operating LLC (collectively, 'WaterBridge')
NDB Midstream LLC is a strategic partnership between Five Point Energy and Devon Energy Corp. (NYSE: DVN) that operates full-cycle produced water transportation, handling, recycling and reuse assets in the northern Delaware Basin in West Texas and New Mexico and the Eagle Ford Basin in South Texas. NDB Midstream LLC handles approximately 1.2 million bpd of produced water and owns 2.0 million bpd of produced water handling capacity.
WaterBridge Operating LLC is a portfolio company of Five Point Energy and GIC that operates full-cycle produced water transportation, handling, recycling and reuse assets in southern Delaware Basin in West Texas and the Arkoma Basin in Oklahoma. WaterBridge Operating LLC handles approximately 1.2 million bpd of produced water and owns 2.2 million bpd of produced water handling capacity.
WaterBridge collectively comprises the largest pure play produced water midstream business in the industry. Headquartered in Houston, Texas, WaterBridge benefits from a first-mover advantage in the emerging water midstream sector with a management team with extensive experience in the water midstream industry. For further information, please visit www.h2obridge.com.
Cautionary Statement Regarding Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on Five Point's beliefs, as well as assumptions made by, and information currently available to, Five Point, and therefore involve risks and uncertainties that are difficult to predict. Generally, future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' or 'may' and the words 'believe,' 'anticipate,' 'continue,' 'intend,' 'expect' and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, strategies, plans, objectives, expectations, intentions, assumptions, future operations and prospects and other statements that are not historical facts, including our estimated future financial performance. You should not place undue reliance on forward-looking statements. Although Five Point believes that plans, intentions and expectations reflected in or suggested by any forward-looking statements made herein are reasonable, Five Point and its portfolio companies, including LandBridge and PowerBridge, may be unable to achieve such plans, intentions or expectations and actual results, and performance or achievements may vary materially and adversely from those envisaged in this news release due to a number of factors including, but not limited to: potential hyperscale customers' demand for and use of LandBridge's land and resources; the success of our affiliates, including LandBridge, PowerBridge, WaterBridge, and the counterparty to the previously disclosed lease development agreement, in executing their business strategies, including their ability to construct infrastructure, attract customers and operate successfully on LandBridge's land; potential customers' willingness and ability to develop LandBridge's land or any potential acquired acreage to accommodate any future surface use developments, such as the site under contract for the data center lease development agreement; LandBridge's ability to enter into favorable contracts regarding surface uses, access agreements and fee arrangements, including the prices LandBridge is able to charge and the margins LandBridge is able to realize; LandBridge's ability to successfully implement its growth plans, including through the future acquisitions of acreage and/or introduction of new revenue streams; PowerBridge's ability to acquire or develop power generation infrastructure; and any changes in general economic and/or industry specific conditions. These risks, as well as other risks associated with LandBridge are also more fully discussed in LandBridge's final prospectus filed with the SEC on March 25, 2025, and LandBridge's subsequent SEC filings. You can access LandBridge's filings with the SEC through the SEC's website at http://www.sec.gov. Except as required by applicable law, neither Five Point nor LandBridge undertakes any obligation to update any forward-looking statements or other statements herein for revisions or changes after this communication is made.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250515364198/en/
CONTACT: Media Contacts
Daniel Yunger / Nathaniel Shahan
Kekst CNC
[email protected]/[email protected]
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: OTHER ENERGY UTILITIES NATURAL RESOURCES HARDWARE ENERGY DATA MANAGEMENT TECHNOLOGY OTHER NATURAL RESOURCES
SOURCE: Five Point Infrastructure LLC
Copyright Business Wire 2025.
PUB: 05/15/2025 08:15 AM/DISC: 05/15/2025 08:16 AM
http://www.businesswire.com/news/home/20250515364198/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Gemini's IPO Filing Signals Crypto Market Maturation
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Gemini announced on Friday that it had confidentially filed for an initial public offering in the U.S., according to Reuters, marking a pivotal moment in the cryptocurrency industry's evolution toward mainstream financial acceptance. This move comes during a particularly favorable window for high-risk sector listings, with improved market conditions creating renewed investor appetite for growth-oriented companies. The timing of Gemini's Friday announcement appears strategically calculated. The cryptocurrency exchange's confidential IPO filing represents a significant milestone in the digital asset industry's maturation, coming at a moment when market sentiment has shifted decisively in favor of risk assets. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . Circle's (NYSE:CRCL) successful public debut last week is a crucial precedent. The stablecoin issuer's 'blowout' performance demonstrates that public markets are ready to embrace well-positioned crypto companies. This success creates a demonstration effect that could encourage a wave of similar listings from digital asset firms that have been waiting on the sidelines. Timing Advantages: Market conditions have improved significantly from the crypto winter of 2022-23 Regulatory clarity has increased, reducing some uncertainty premium Institutional adoption of digital assets continues to grow The successful Circle IPO has validated investor interest Potential Challenges: Crypto markets remain highly volatile, which could affect valuation Regulatory landscape continues evolving Competition from established players like Coinbase (NASDAQ:COIN) and Binance Need to demonstrate sustainable revenue models beyond trading fees Trending: New to crypto? on Coinbase. This IPO filing reflects several important trends: Industry Maturation: Crypto companies are increasingly seeking traditional capital market access, signaling the sector's evolution from speculative frontier to established financial services category. Investor Sentiment Shift: The renewed appetite for high-risk sector IPOs suggests risk-on sentiment has returned after a period of market caution. Regulatory Progress: Companies feel sufficiently confident in the regulatory environment to pursue public listings, indicating improved clarity around compliance requirements. For Retail Investors: Crypto-related stocks offer exposure to digital asset growth without direct cryptocurrency ownership Consider these investments as part of a diversified portfolio's higher-risk allocation Monitor regulatory developments that could impact business models For Financial Professionals: Evaluate client suitability for crypto-adjacent equity investments Consider correlation risks with both traditional tech stocks and cryptocurrency markets Assess liquidity and volatility profiles compared to direct crypto exposure Key Takeaways Gemini's IPO filing, following Circle's successful debut, suggests the crypto industry is entering a new phase of mainstream financial market integration. While this represents significant progress for the sector, investors should remain mindful of the inherent volatility and regulatory uncertainties that continue to characterize digital asset markets. The success of these offerings will likely determine whether we see a broader wave of crypto IPOs or a more selective approach based on market reception and regulatory developments. Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article Gemini's IPO Filing Signals Crypto Market Maturation originally appeared on Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Yahoo
an hour ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
